Related references
Note: Only part of the references are listed.Shared and independent roles of CGRP and PACAP in migraine pathophysiology
Adisa Kuburas et al.
JOURNAL OF HEADACHE AND PAIN (2023)
Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis
Diego Belandrino Swerts et al.
PAIN (2022)
Novel synthetic treatment options for migraine
Andrea Negro et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis
Konstantina Drellia et al.
CEPHALALGIA (2021)
Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis
Lili Kokoti et al.
JOURNAL OF NEUROLOGY (2020)
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis
Raeburn B. Forbes et al.
HEADACHE (2020)
European Headache Federation recommendations for placebo and nocebo terminology
Dimos D. Mitsikostas et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Gepants for the treatment of migraine
Andrea Negro et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review
David Moreno-Ajona et al.
HEADACHE (2019)
Comparing the efficacy of disease-modifying therapies in multiple sclerosis
Dimos D. Mitsikostas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches
Dimos D. Mitsikostas et al.
CEPHALALGIA (2011)